596 related articles for article (PubMed ID: 26549145)
1. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
2. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
3. Chemical modification of siRNA.
Deleavey GF; Watts JK; Damha MJ
Curr Protoc Nucleic Acid Chem; 2009 Dec; Chapter 16():Unit 16.3. PubMed ID: 20013783
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of chemically modified siRNA: Recent trends.
Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
[TBL] [Abstract][Full Text] [Related]
5. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
De Paula D; Bentley MV; Mahato RI
RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
[TBL] [Abstract][Full Text] [Related]
6. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
7. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications.
Gangopadhyay S; Gore KR
RNA Biol; 2022 Jan; 19(1):452-467. PubMed ID: 35352626
[TBL] [Abstract][Full Text] [Related]
8. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
[TBL] [Abstract][Full Text] [Related]
9. [Chemical Approaches for RNAi Drug Development].
Saito-Tarashima N
Yakugaku Zasshi; 2020; 140(10):1259-1268. PubMed ID: 32999205
[TBL] [Abstract][Full Text] [Related]
10. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.
Fluiter K; Mook OR; Baas F
Methods Mol Biol; 2009; 487():189-203. PubMed ID: 19301648
[TBL] [Abstract][Full Text] [Related]
12. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
Gangopadhyay S; Nikam RR; Gore KR
Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
[TBL] [Abstract][Full Text] [Related]
13. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in chemically modified siRNAs.
Gaglione M; Messere A
Mini Rev Med Chem; 2010 Jun; 10(7):578-95. PubMed ID: 20500149
[TBL] [Abstract][Full Text] [Related]
15. siRNA applications in nanomedicine.
Tokatlian T; Segura T
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):305-15. PubMed ID: 20135697
[TBL] [Abstract][Full Text] [Related]
16. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
17. Structural modification of siRNA for efficient gene silencing.
Lee SJ; Son S; Yhee JY; Choi K; Kwon IC; Kim SH; Kim K
Biotechnol Adv; 2013; 31(5):491-503. PubMed ID: 22985697
[TBL] [Abstract][Full Text] [Related]
18. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
19. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
Marinho HS; Marcelino P; Soares H; Corvo ML
Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
[TBL] [Abstract][Full Text] [Related]
20. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
